mutation class

Gene Rearrangement

A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

64 sites for NCT04307576

ABL1 Fusion, +11 more biomarkers

Acute Lymphoblastic Leukemia

blinatumomab, +7 more drugs

chemotherapy, +3 more types

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

63 sites for NCT04501614

ABL1 Fusion, +31 more biomarkers

Acute Lymphoblastic Leukemia, +1 more condition

chemotherapy, +1 more drug

chemotherapy, +1 more type

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

6 sites for NCT03117751

ABL1 Fusion, +28 more biomarkers

Acute Lymphoblastic Leukemia, +8 more conditions

asparaginase Erwinia chrysanthemi, +21 more drugs

cellular therapy, +4 more types

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

97 sites for NCT02723994

ABL1 Fusion, +25 more biomarkers

B-Cell Acute Lymphoblastic Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT

1 site for NCT04959903

ABL1 Fusion, +69 more biomarkers

Acute Lymphoblastic Leukemia, +1 more condition

allogeneic hematopoietic stem cell transplantation

cellular therapy

bosutinib +/- induction therapy

ABL1 Fusion

Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

bosutinib, +1 more drug

Other, +1 more type

dasatinib + chemotherapy

ABL1 Fusion, +7 more biomarkers

B-Cell Acute Lymphoblastic Leukemia

Consolidation, +1 more context

chemotherapy, +1 more drug

chemotherapy, +1 more type

dasatinib +/- induction therapy

ABL1 Fusion

Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

dasatinib, +1 more drug

Other, +1 more type

imatinib +/- induction therapy

ABL1 Fusion

Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

imatinib, +1 more drug

Other, +1 more type

nilotinib +/- induction therapy

ABL1 Fusion

Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

induction therapy, +1 more drug

Other, +1 more type

ponatinib +/- induction therapy

ABL1 Fusion

Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

induction therapy, +1 more drug

Other, +1 more type